JP Morgan | GenomeWeb

JP Morgan

The gene editing firm has sold all 5.9 million shares offered to the public as well as 885,000 shares in the fully exercised over-allotment option to the underwriters.

Westin St. Francis Hotel, San Francisco, site of the JP Morgan Healthcare Conference

Executives from Luminex, Exact Sciences, T2 Biosystems, and Singulex provided updates on their companies' businesses on the final day of the conference.

The chemistry will be single-molecule, based on hybridization, and will not require amplification, enzymes, or library prep, the firm said.

Executives from Thermo Fisher Scientific, Qiagen, Danaher, Counsyl, Human Longevity, and Adaptive Biotechnologies provided business updates to conference goers.

Executives from the sequencing tech firms provided attendees with an update on recently launched products and platforms, and future technology developments.

Executives from 23andMe, Myriad Genetics, Genomic Health, and Alere provided updates on their companies at the JP Morgan Healthcare Conference in San Francisco.

The company also announced the Infinium XT genotyping array for analyzing large sample numbers, and provided preliminary earnings for Q4 and full-year 2015.

The amendment to a 2013 debt financing agreement will increase revolving commitments to $1.3 billion, extend maturity of loans, and adjust interest rates and fees.

By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – Citing expected organic growth and a continuing ramp up of QIAsymphony, investment bank JP Morgan today upgraded Qiagen to Overweight.

Pages

In Science this week: genetic analysis of pollutant-tolerant fish, and more.

Researchers have found a rare carbapenem resistance gene on a US pig farm, NBC News reports.

New York officials are considering the use of a familial DNA search to get a lead on a suspect in the strangulation death of a runner.

NIH Director Francis Collins has selected a retired Army major general and cardiologist for the CEO spot at the agency's embattled Clinical Center.